AMP Capital Investors Ltd boosted its position in shares of CytomX Therapeutics Inc (NASDAQ:CTMX) by 64.7% in the 4th quarter, Holdings Channel reports. The firm owned 66,621 shares of the biotechnology company’s stock after buying an additional 26,183 shares during the quarter. AMP Capital Investors Ltd’s holdings in CytomX Therapeutics were worth $1,406,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the business. Algert Global LLC raised its holdings in CytomX Therapeutics by 11.7% during the 4th quarter. Algert Global LLC now owns 51,233 shares of the biotechnology company’s stock worth $1,082,000 after purchasing an additional 5,380 shares during the last quarter. New York State Common Retirement Fund raised its holdings in CytomX Therapeutics by 18.6% during the 3rd quarter. New York State Common Retirement Fund now owns 36,900 shares of the biotechnology company’s stock worth $670,000 after purchasing an additional 5,800 shares during the last quarter. Bank of Montreal Can bought a new stake in CytomX Therapeutics during the 4th quarter worth about $124,000. Macquarie Group Ltd. bought a new stake in CytomX Therapeutics during the 3rd quarter worth about $107,000. Finally, The Manufacturers Life Insurance Company raised its holdings in CytomX Therapeutics by 36.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,529 shares of the biotechnology company’s stock worth $365,000 after purchasing an additional 6,342 shares during the last quarter. 78.07% of the stock is owned by hedge funds and other institutional investors.
Shares of CytomX Therapeutics stock opened at $31.56 on Friday. The company has a market capitalization of $1,252.55, a PE ratio of -26.75 and a beta of 0.76. CytomX Therapeutics Inc has a 52 week low of $13.00 and a 52 week high of $35.00.
Several brokerages have weighed in on CTMX. Zacks Investment Research cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, February 5th. Cantor Fitzgerald set a $40.00 price objective on CytomX Therapeutics and gave the stock a “buy” rating in a report on Saturday, March 17th. Citigroup initiated coverage on CytomX Therapeutics in a report on Friday, January 5th. They set a “buy” rating and a $40.00 price objective for the company. BidaskClub raised CytomX Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 7th. Finally, Jefferies Group upped their price target on CytomX Therapeutics to $40.00 and gave the company a “buy” rating in a research note on Thursday, March 8th. Two analysts have rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. CytomX Therapeutics has a consensus rating of “Buy” and an average price target of $36.13.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics Inc (NASDAQ:CTMX).
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.